Extended follow-up of 60 patients with resectable stage IB-IIIA NSCLC given preoperative nivolumab with or without relatlimab: 3-year OS 88.4% vs 88.9% and DFS 73.3% vs 60.3%, at a median follow-up of 37.4 months.
RCTn = 60
Cuppens et al. Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)